Trastuzumab Emtansine(T-DM1) After Trastuzumab Deruxtecan(T-DXd) in HER2-Positive Breast Cancer in Korea
RecruitingOBSERVATIONAL
Enrollment
100
Participants
Timeline
Start Date
February 26, 2025
Primary Completion Date
September 30, 2028
Study Completion Date
September 30, 2029
Conditions
Cancer of BreastTrastuzumab EmtansineTrastuzumab Deruxtecan
Trial Locations (1)
03080
RECRUITING
Seoul National University Hospital, Seoul
All Listed Sponsors
lead
Seoul National University Hospital
OTHER
NCT06928818 - Trastuzumab Emtansine(T-DM1) After Trastuzumab Deruxtecan(T-DXd) in HER2-Positive Breast Cancer in Korea | Biotech Hunter | Biotech Hunter